4519 Stock Overview
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for 4519 from our risk checks.
Chugai Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥5,927.00 |
52 Week High | JP¥6,697.00 |
52 Week Low | JP¥3,203.00 |
Beta | 0.48 |
1 Month Change | -1.35% |
3 Month Change | 10.04% |
1 Year Change | 80.59% |
3 Year Change | 32.03% |
5 Year Change | 143.58% |
Change since IPO | 1,311.19% |
Recent News & Updates
Shareholder Returns
4519 | JP Pharmaceuticals | JP Market | |
---|---|---|---|
7D | -2.2% | 0.2% | 1.7% |
1Y | 80.6% | 16.5% | 37.6% |
Return vs Industry: 4519 exceeded the JP Pharmaceuticals industry which returned 16.6% over the past year.
Return vs Market: 4519 exceeded the JP Market which returned 38.6% over the past year.
Price Volatility
4519 volatility | |
---|---|
4519 Average Weekly Movement | 4.6% |
Pharmaceuticals Industry Average Movement | 3.8% |
Market Average Movement | 3.9% |
10% most volatile stocks in JP Market | 8.4% |
10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4519 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4519's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1925 | 7,771 | Osamu Okuda | https://www.chugai-pharm.co.jp |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases.
Chugai Pharmaceutical Co., Ltd. Fundamentals Summary
4519 fundamental statistics | |
---|---|
Market cap | JP¥9.75t |
Earnings (TTM) | JP¥325.47b |
Revenue (TTM) | JP¥1.11t |
30.0x
P/E Ratio8.8x
P/S RatioIs 4519 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4519 income statement (TTM) | |
---|---|
Revenue | JP¥1.11t |
Cost of Revenue | JP¥413.31b |
Gross Profit | JP¥698.06b |
Other Expenses | JP¥372.59b |
Earnings | JP¥325.47b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 24, 2024
Earnings per share (EPS) | 197.82 |
Gross Margin | 62.81% |
Net Profit Margin | 29.29% |
Debt/Equity Ratio | 0% |
How did 4519 perform over the long term?
See historical performance and comparison